Contributions
Abstract: PB1620
Type: Publication Only
Background
The prognosis of acute lymphoblastic leukemia (ALL) in children is greatly improved by identification of prognostic factors and better stratification in risk group. Through this study we specify the interest of the minimal residual disease (MRD) by flow cytometry in patients treated for ALL.
Aims
In our study, we evaluated the response of treatment in acute lymphoblastic leukemia of child by analyzed of minimal residual disease with flow cytometry.
Methods
In our study we are interested at the results of MRD performed by flow cytometry (CMF) on two points: Day 36 (TP1) and Day 63 (TP2), in children treated for ALL according to the protocol EORTC 58951 from January 2015 to June 2017. MRD is considered positive when TP1> 10-2 and TP2> 10-3. Then we observed the impact of the MRD on relapse.
Results
We collected 45 cases of ALL who received an MDR response assessment. These are 33 boys and 12 girls (sex ratio = 2.75). The median age at diagnosis was 8 years (2- 29 years). There are 32 cases of B phenotype and 13 cases of T phenotype. The median rate of WBC was 11G / L. Two patients are classified LR, 18 AR1, 13 AR2 and 12 HR. 44 patients (98%) achieved a complete remission after induction and one patient was in therapeutic failure. TP1 was done for 40 patients (89%), TP2 achievement rate was 78% and 67% of patients have the 2 points (TP1 and TP2). For the patients who had TP1: 2 were positive and relapsed, 27 patients were negative of which 9 (24%) relapsed (p = 0.061). Of the 35 patients who had TP2, 9 were positive, of which 3 (33%) relapsed and 26 had TP2 negative, 7 of them (27%) relapsed (p=0.033). Of the 38 TP1 negative patients, 28 had a second point among them 6 patients had TP2 positive, of which 4 patients (67%) relapsed.
Conclusion
The MRD study is currently an element determinant in the prognosis of ALL. In our series, this study was conducted by CMF for lack of molecular biology. It shows an interest in the occurrence of relapse as well as in the literature. We plan to expand this study and make it protocol for all our patients and especially the involved in the therapeutic attitude.
Session topic: 1. Acute lymphoblastic leukemia – Biology & Translational Research
Keyword(s): Acute lymphoblastic leukemia, flow cytometry, Minimal residual disease (MRD)
Abstract: PB1620
Type: Publication Only
Background
The prognosis of acute lymphoblastic leukemia (ALL) in children is greatly improved by identification of prognostic factors and better stratification in risk group. Through this study we specify the interest of the minimal residual disease (MRD) by flow cytometry in patients treated for ALL.
Aims
In our study, we evaluated the response of treatment in acute lymphoblastic leukemia of child by analyzed of minimal residual disease with flow cytometry.
Methods
In our study we are interested at the results of MRD performed by flow cytometry (CMF) on two points: Day 36 (TP1) and Day 63 (TP2), in children treated for ALL according to the protocol EORTC 58951 from January 2015 to June 2017. MRD is considered positive when TP1> 10-2 and TP2> 10-3. Then we observed the impact of the MRD on relapse.
Results
We collected 45 cases of ALL who received an MDR response assessment. These are 33 boys and 12 girls (sex ratio = 2.75). The median age at diagnosis was 8 years (2- 29 years). There are 32 cases of B phenotype and 13 cases of T phenotype. The median rate of WBC was 11G / L. Two patients are classified LR, 18 AR1, 13 AR2 and 12 HR. 44 patients (98%) achieved a complete remission after induction and one patient was in therapeutic failure. TP1 was done for 40 patients (89%), TP2 achievement rate was 78% and 67% of patients have the 2 points (TP1 and TP2). For the patients who had TP1: 2 were positive and relapsed, 27 patients were negative of which 9 (24%) relapsed (p = 0.061). Of the 35 patients who had TP2, 9 were positive, of which 3 (33%) relapsed and 26 had TP2 negative, 7 of them (27%) relapsed (p=0.033). Of the 38 TP1 negative patients, 28 had a second point among them 6 patients had TP2 positive, of which 4 patients (67%) relapsed.
Conclusion
The MRD study is currently an element determinant in the prognosis of ALL. In our series, this study was conducted by CMF for lack of molecular biology. It shows an interest in the occurrence of relapse as well as in the literature. We plan to expand this study and make it protocol for all our patients and especially the involved in the therapeutic attitude.
Session topic: 1. Acute lymphoblastic leukemia – Biology & Translational Research
Keyword(s): Acute lymphoblastic leukemia, flow cytometry, Minimal residual disease (MRD)